LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
LUNG-ROLL
1 other identifier
observational
60,000
1 country
2
Brief Summary
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2025
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2025
CompletedStudy Start
First participant enrolled
August 20, 2025
CompletedFirst Posted
Study publicly available on registry
August 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2027
March 2, 2026
February 1, 2026
2.1 years
May 30, 2025
February 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Treatment patterns
Through study completion, an average of 1 year
Secondary Outcomes (7)
Incidence and prevalence
Through study completion, an average of 1 year
Baseline demographic and clinical characteristics
Through study completion, an average of 1 year
Overall survival
Through study completion, an average of 6 months
Time to/on therapy
Through study completion, an average of 6 months
Attrition rates
Through study completion, an average of 1 year
- +2 more secondary outcomes
Study Arms (2)
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Eligibility Criteria
Study population will comprise patients with lung cancer diagnosed after January 1, 2018 in the administrative databases for Alberta and Ontario.
You may qualify if:
- Patients with lung cancer between January 1, 2018 and end of the Selection Period.
- Patient is 18 years of age or older on diagnosis date.
- Patient has at least 12 months of health insurance coverage prior to the diagnosis date.
You may not qualify if:
- Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
- Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
- Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
- Non-Ontario or non-Alberta resident on diagnosis date.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (2)
Research Site
Calgary, Alberta, T2N1N4, Canada
Research Site
Toronto, Ontario, M5T3M6, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2025
First Posted
August 27, 2025
Study Start
August 20, 2025
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
September 30, 2027
Last Updated
March 2, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share